Total Gastrectomy - Stomach Removal Surgery
Total gastrectomy removes the whole stomach for cancer, with chemotherapy before and after surgery, D2 lymph node removal and a plan for eating afterwards.
About This Department
Total gastrectomy, stomach removal surgery, takes out the whole stomach and joins the esophagus to the small bowel. Chemotherapy before and after the operation adds years to survival in stomach cancer.
Stomach cancer in the upper or middle stomach, or one that spreads through the whole wall, needs the entire stomach removed with its lymph nodes. In the MAGIC trial, five-year survival rose from 23 to 36 percent when chemotherapy came before and after surgery, and the FLOT4 trial raised median survival further, to 50 months. Life without a stomach means smaller meals and vitamin B12 for good. Send your endoscopy, biopsy and CT reports, and our team will tell you whether a total or a partial gastrectomy fits.
A total gastrectomy removes the whole stomach, the fatty apron attached to it and the lymph nodes around its blood vessels. The surgeon then brings a loop of small bowel up to the esophagus, so food passes straight from the gullet into the bowel.
What the stomach does
The authors believe that SG, which has been reported to be associated with a better nutritional status and quality of life, should be the procedure of choice, provided that the proximal margin of the resection falls in healthy tissue.Italian randomized trial of 618 patients, Annals of Surgery, 1999
Total or subtotal
Total against subtotal gastrectomy
For lower stomach cancer, an Italian trial answered whether removing the whole stomach adds safety.
The Italian trial
Five-year survival
The numbers side by side.
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| Outcome | Subtotal | Total |
|---|---|---|
| Survival at five years | 65.3 percent | 62.4 percent |
| Deaths after surgery | 4 patients | 7 patients |
| Verdict | Equivalent | Equivalent |
Who needs a total gastrectomy
Adenocarcinoma of the upper or middle stomach accounts for the large majority. A smaller group carries an inherited change in the CDH1 gene.
Hereditary diffuse gastric cancer
Chemotherapy before and after surgery
For any stomach cancer beyond the earliest stage, treatment starts with chemotherapy, and surgery follows. Staging comes first.
- Endoscopy with biopsy, including tests that guide drug choice.
- CT of the chest, abdomen and pelvis.
- Endoscopic ultrasound for depth of invasion.
- Diagnostic laparoscopy, to find spread on the lining of the abdomen that scans miss.
The MAGIC trial
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| Trial | Comparison | Result |
|---|---|---|
| MAGIC, 503 patients | ECF chemotherapy with surgery against surgery alone | Five-year survival 36 against 23 percent |
| FLOT4, 716 patients | FLOT against ECF or ECX chemotherapy, both with surgery | Median survival 50 against 35 months |
The operation
Under general anesthesia, by keyhole or open surgery, the surgeon divides the stomach from the esophagus above and the duodenum below, removes it with its lymph nodes, and joins a Roux loop of small bowel to the esophagus with a circular stapler. The operation takes four to six hours. A feeding tube into the bowel goes in for some patients, to support nutrition in the first weeks. Then intensive care for the first night. Every specimen goes to the pathologist, who counts the lymph nodes and checks the margins, and that report decides the chemotherapy after surgery.
Lymph node removal
Stomach cancer spreads first to the lymph nodes along the stomach and its arteries. A D1 operation removes the nodes next to the stomach, a D2 operation also those along the main arteries behind it.
The Dutch D1D2 trial
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| Outcome | D1 | D2 |
|---|---|---|
| Survival at 15 years | 21 percent | 29 percent, difference short of significance |
| Death from stomach cancer | 48 percent | 37 percent |
| Local recurrence | 22 percent | 12 percent |
| Deaths after surgery | 4 percent | 10 percent |
| Complications | 25 percent | 43 percent |
After a median follow-up of 15 years, D2 lymphadenectomy is associated with lower locoregional recurrence and gastric-cancer-related death rates than D1 surgery.Dutch D1D2 trial, Lancet Oncology, 2010
Keyhole surgery, recovery and life without a stomach
Keyhole total gastrectomy means five or six small incisions and a short one for the specimen.
The CLASS02 trial
- A leak from the join between esophagus and bowel.
- Bleeding.
- Infection in the abdomen or chest.
- A leak of pancreatic fluid after lymph node removal.
- Blood clots, lowered by early walking and blood thinner injections.
The results of the CLASS02 trial showed that the safety of LTG with lymphadenectomy by experienced surgeons for clinical stage I gastric cancer was comparable to that of OTG.CLASS02 trial, JAMA Oncology, 2020
Before you eat
Vitamins and blood
Lifelong supplements
Dumping syndrome
Weight and diet
Dumping and how to avoid it
The first months
Results of chemotherapy around surgery
The FLOT4 trial
In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.MAGIC trial, New England Journal of Medicine, 2006
Risks in numbers and the stay in Istanbul
The stay in Istanbul
The D2 procedure was also associated with significantly higher postoperative mortality, morbidity, and reoperation rates.Dutch D1D2 trial, Lancet Oncology, 2010
Total gastrectomy FAQ
Can you live a normal life without a stomach?
How much weight will I lose after a total gastrectomy?
Do I need chemotherapy before stomach removal surgery?
Can a total gastrectomy be done by keyhole surgery?
How long is the hospital stay?
References
- Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Annals of Surgery. 1999;230(2):170-178.
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine. 2006;355(1):11-20.
- Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957.
- Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology. 2010;11(5):439-449.
- Liu F, Huang C, Xu Z, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage I gastric cancer: the CLASS02 multicenter randomized clinical trial. JAMA Oncology. 2020;6(10):1590-1597.
Editor's note
Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Özcan YILDIZ, Medical Oncology.
Medically reviewed by
Prof. Dr. Özcan YILDIZ
Medical Oncology
Last updated: